Novo provides update on the denecimig Biologics License Application (BLA) in the US Bagsværd, Denma...

Novo provides update on the denecimig Biologics License Application (BLA) in the US Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.